Atlas Genetics Secures CE Mark for Rapid Point of Care Diagnostic

Atlas Genetics Secures CE Mark for Rapid Point of Care Diagnostic

April 2016

42 Technology congratulated Atlas Genetics (now Binx Health), on receiving approval to CE mark its Chlamydia Trachomatis Point-Of-Care test, which 42 Technology helped to develop.

Using the company’s io® platform (which received a CE Mark in 2014), the CT test offers performance equivalent to the gold standard laboratory test, but in a POC setting, and delivers test results in just 30 minutes, enabling diagnosis during the clinic visit.

The io™ system (video) consists of a low-cost easy-to-use automated instrument and a disposable cartridge. Following the addition of an unprocessed patient specimen on to the io™ cartridge, the cartridge is then inserted in to the io™ Reader, allowing the test to be completed with minimal hands on time. 42 Technology worked with Atlas Genetics on the development of the cartridge, in areas concerning the cartridge fluidics.


Tests for more infections are in development, including other Sexually Transmitted Infections (STIs) and Hospital Acquired Infections (HAIs) such as MRSA.

Share this article:

What will you ask us today?

We believe in asking the right questions to drive innovation; when we know the right questions, we generate the ideas to answer them.